Silibinin (an ingredient in Milk Thistle)

Property	Information
Drug Name	Silibinin (Silymarin)
FDA Approval	No
Used for	Liver and biliary disorders, adjunct agent in cancer treatment
Clinical Trial Phase	Investigated primarily in hepatitis and cirrhosis; small studies in cancers such as acute lymphoblastic leukemia, prostate cancer, breast cancer, head and neck cancer, and hepatocellular carcinoma
Clinical Trial Explanation	Not specified
Common Side Effects	Few reported; mainly gastrointestinal disturbances
OS without	Not specified
OS with	Not specified
PFS without	Not specified
PFS with	Not specified
Usefulness Rating	Under investigation; shown to have anti-cancer effects in laboratory studies
Usefulness Explanation	Not specified
Toxicity Level	Low
Toxicity Explanation	Silibinin is considered to have few side effects, with gastrointestinal disturbances being the most common.

Notes: Silibinin, the active component of Milk Thistle, has shown potential in stabilizing cellular membranes, stimulating detoxification pathways, and inhibiting cancer cell growth in laboratory studies. It has a long history of use for liver and biliary disorders. Clinical trials in cancer are limited but suggest a potential role in enhancing chemotherapy efficacy and reducing toxicity.

Links: * [Milk Thistle (PDQ®)–Health Professional Version - NCI](https://www.cancer.gov/about-cancer/treatment/cam/hp/milk-thistle-pdq)

From Ben Williams Book: Not specified

Loading comments...